AMANDA MABUS: Open Payments
NPI 1609181056 · SPRINGFIELD, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,180 in 40 payments from 12 companies in 2025. Trend: 2023 $66 · 2024 $179 · 2025 $1,180
Food & beverage: $1,085Education: $95
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $429 |
| Madrigal Pharmaceuticals | 3 | $305 |
| Janssen Biotech, Inc. | 4 | $222 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| GENZYME CORPORATION | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
Products named: REZDIFFRA, TREMFYA, SKYRIZI, XIFAXAN, RINVOQ, DUPIXENT, LINZESS, ZENPEP.
Industry payments across IL — which companies pay providers there.
